News
Illumina Stock: Shares Hit New Low Despite Growth Plans
Illumina's stock has plummeted to a 52-week low of $94.72, marking a significant 28% decline from the previous year, despite the biotechnology company's robust annual revenue of $4.37 billion and
Unitedhealth Stock: DoJ Probe Triggers 11% Share Plunge
The healthcare insurance giant Unitedhealth experienced a dramatic 11% stock decline on Friday following the announcement of a civil fraud investigation by the U.S. Department of Justice (DoJ). The
Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Medtronic’s (NYSE: MDT) growth efforts and investments in medical technology innovation are starting to pay off. The company's pulsed field ablation (PFA) technology is a key growth driver
AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies
AstraZeneca is bolstering its presence in the Chinese healthcare sector through a strategic acquisition worth $160 million, purchasing FibroGen's Chinese subsidiary. The deal, structured with an
Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Health insurance giant Humana Inc. (NYSE: HUM) stock initially rose in reaction to its fourth quarter of 2024 earnings report despite posting losses.
The medical sector giant was one of the
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology
Illumina Aktie: Keine Panikmache, einfach Fakten
Der US-Gentechnikspezialist Illumina verzeichnet aktuell eine gemischte Entwicklung an den Börsen. Der Aktienkurs liegt derzeit bei 103,00 USD und konnte einen Tagesgewinn von 1,89 Prozent
Eli Lilly and Stock: Strategic $2B Acquisition Targets Weight Loss Market
Eli Lilly and is strengthening its position in the lucrative weight management sector through a significant $2 billion acquisition of Versanis Bio. This strategic move centers on Bimagrumab, a
Biomarin Pharmaceutical Stock: Q4 Profits Soar, 2025 Outlook Strong
Biomarin Pharmaceutical has demonstrated remarkable financial performance in the fourth quarter, with net profits reaching $125 million, translating to earnings per share of $0.64—a substantial
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came
UnitedHealth Stock: FTC Scrutiny Triggers 4.6% Share Decline
UnitedHealth Group experienced a significant market setback as its shares plummeted 4.6% amid mounting concerns over its planned acquisition of Amedisys. The downturn stems from the Federal Trade
Johnson & Johnson Stock: Debt Concerns Rise After Strategic Acquisitions
Johnson & Johnson's financial stability faces new scrutiny as S&P Global Ratings places the healthcare giant's newly issued senior unsecured bonds under negative watch, despite maintaining their
Gilead Sciences Stock: FDA Fast-Tracks HIV Drug Review
Gilead Sciences experienced a notable uptick in its NASDAQ trading performance, with shares climbing 1.5% to reach $105.60. This movement brings the stock close to its 52-week high of $106.68
Hims & Hers: From Viral Ad to Volatile Stock
Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 weeks. Shares are down 34% over that period as of the Feb. 13 close. The
Stryker Aktie: Ein Durchbruch mit Potenzial!
Die Stryker Corporation zeigt sich zum Jahresanfang 2025 in robuster Verfassung. Der Medizintechnikkonzern konnte im abgeschlossenen Geschäftsjahr 2024 einen beachtlichen Umsatzanstieg von 10
Bayer AG Stock: Share Price Drops Amid Dividend Cuts
Bayer AG continues to face significant market challenges as its stock price remains under pressure, dropping to €21.54 on XETRA trading, marking a 0.4 percent decline. This performance stands in
Johnson & Johnson Aktie: Was jüngst diskutiert wird
Die Pharmasparte von Johnson & Johnson sorgte diese Woche für Aufsehen mit der Bekanntgabe des vorzeitigen Abbruchs ihrer Phase-3-Studie E.mbrace am 13. Februar 2025. Der Gesundheitskonzern, dessen
Eli Lilly and Aktie: Versorgungsketten aktuell betrachtet
Die Eli Lilly and Company hat zum 14. Februar 2025 ihre vierteljährliche Dividende auf 1,50 USD erhöht, was einer deutlichen Steigerung gegenüber der November-Ausschüttung von 1,30 USD entspricht
Biotechs on the Brink: 2 Stocks With Huge Potential
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug
Zoetis Stock: Weak 2025 Outlook Triggers Sharp Decline
Zoetis, the leading veterinary pharmaceutical company, demonstrated robust performance in the fourth quarter with revenue climbing 5 percent to $2.3 billion. The adjusted earnings per share reached
Gilead Sciences Stock: Shares Near 52-Week High Amid Growth
Gilead Sciences is experiencing remarkable momentum on the NASDAQ, with its stock currently trading at $105.25, approaching its 52-week peak of $105.37. The biotechnology company has demonstrated
Boston Scientific Stock: Executives Sell Shares Near Record High
Boston Scientific Corporation's stock continues to demonstrate remarkable momentum, trading close to its 52-week peak of $107.17 and boasting an impressive year-to-date performance exceeding 62%
EQS-HV: Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 26.03.2025 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio
AbbVie has significantly strengthened its oncology portfolio through a groundbreaking collaboration with Xilio Therapeutics, marking a major expansion into cancer immunotherapy development. The